Key result
Single subcutaneous doses of RO-11 (7,500 to 12,500 i.u.) produced a dose-dependent anti-FXa response peaking at 3-6 hours with a half-life >5 hours and no clinically relevant clotting prolongation.
Why the study?
Does RO-11 demonstrate dose-dependent pharmacokinetics and tolerability in healthy volunteers?
Does RO-11 demonstrate dose-dependent pharmacokinetics and tolerability in healthy volunteers?
Answers are grounded in this paper and cite their sources.
RO-11, a new low molecular mass heparin, demonstrates favorable pharmacokinetics and tolerability in healthy volunteers, supporting a 7,500 i.u. single daily dose for future DVT and PE trials.
This paper reports on the results of a Phase I, dose-finding study with a new low molecular mass heparin (LMMH) called RO-11. The study focused on pharmacokinetics, dose-effect relationship and on tolerability of three single subcutaneous (s.c.) doses within the therapeutical range. After the injection of 7,500, 9,000 and 12,500 anti-FXa i.u., the anti-FXa effect peaked between 3-6 h and showed a dose-dependent response. The absorption and elimination were first-order processes and the long half-life (> 5 h) kept constant after increasing doses. The compound was tolerated very well and no clinically relevant prolongation of APTT, prothrombin and thrombin clotting tests was observed. At the dose of 7,500 i.u., which corresponded to 110 anti-FXa i.u./Kg, RO-11 exerted anti-FXa effect for at least 18-20 h. We recommend using this dose in a single s.c. injection, to evaluate the efficacy and safety of RO-11 in the initial treatment of DVT or PE.
No takes yet. Share an insight, caveat, or question.
Falkon et al. (1997) studied Healthy Volunteers. RO-11 was evaluated on Pharmacokinetics, dose-effect relationship and tolerability. Single subcutaneous doses of RO-11 (7,500 to 12,500 i.u.) produced a dose-dependent anti-FXa response peaking at 3-6 hours with a half-life >5 hours and no clinically relevant clotting prolongation.
Synapse has enriched 10 related papers. Consider them for comparative context: